Yamo Pharmaceuticals   Report issue

For profit Phase 2
Founded: New York NY United States (2015)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2016
NCT02947048
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Yamo Pharmaceuticals LLC

Active Ingredients

Drugs in Phase 2 Trials (1)

l1-79 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autistic Disorder (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1